This is Part 1 of 5 in the “The Weight of Empire: Novo Nordisk’s Fight for Survival” series.
On a gray morning in Bagsvaerd, Denmark, Lars Fruergaard Jorgensen stood at the window of his corner office and watched construction cranes swing across the skyline – each one building something for Novo Nordisk, each one a monument to the empire he had built. He did not yet know that every crane would soon feel like a gravestone.
It was June 2024, and the world could not stop talking about his company. Late-night hosts made jokes about Ozempic. Celebrities denied using it, then admitted it, then endorsed it. TikTok teenagers posted transformation videos set to pop music. Senators debated whether Medicare should cover it. And through it all, the stock price kept climbing – past LVMH, past ASML, past every other European company that had ever existed – until Novo Nordisk sat alone at the top of the continent’s market capitalization rankings, a Danish pharmaceutical firm worth more than the GDP of most nations.
Jorgensen turned from the window and looked at the framed photograph on his desk: the entire leadership team, taken at the annual retreat in Skagen the previous September. Everyone smiling. Everyone confident. He remembered the toast he had given that evening, standing on the terrace of a rented villa with the North Sea crashing behind him. “We are not just making drugs,” he had said, raising his glass. “We are rewriting the relationship between medicine and human desire.” The applause had been genuine. The belief had been absolute.
He checked his watch. The investor call was in forty minutes.
Six thousand kilometers away, in Indianapolis, a different kind of energy was building. Eli Lilly’s headquarters hummed with the particular electricity of a company that smells blood. Their drug, Zepbound – the same tirzepatide molecule marketed as Mounjaro for diabetes – had just posted clinical trial results showing average weight loss of 22.5% in obese patients. Novo Nordisk’s semaglutide, the molecule behind both Ozempic and Wegovy, delivered roughly 15%.
The numbers were not ambiguous. They were not subject to interpretation or spin. Lilly’s drug made people lose more weight, and in the pharmaceutical industry, efficacy was the only argument that could not be talked away.
At Novo Nordisk’s commercial headquarters, the Lilly data landed like a mortar round. Jorgensen’s team had known competition was coming – it always did in pharma – but they had expected it to arrive gradually, through inferior products from second-tier companies. Instead, it arrived from America’s most disciplined pharmaceutical company, with a molecule that worked through a dual mechanism Novo’s pipeline could not yet match.
“We have a response?” Jorgensen asked during the Monday morning leadership meeting.
“CagriSema,” said the head of R&D, referring to Novo’s next-generation combination drug. “Phase three data should be ready by December.”
“Should be.”
“Will be.”
Jorgensen nodded. CagriSema was the company’s great bet – a combination of semaglutide and cagrilintide that was supposed to leapfrog Zepbound. It was, in the language of the industry, a pipeline asset of extraordinary value. In the language of corporate survival, it was the only thing standing between Novo Nordisk and the beginning of the end.
The Novo Nordisk Foundation occupied a handsome building on Tuborg Havnevej, a few kilometers from the company headquarters. It was, by design, unassuming – clean Danish lines, restrained landscaping, the kind of architecture that communicated seriousness without ostentation. Inside, the atmosphere matched. Foundation employees spoke in measured tones. Meetings started on time and ended early. The mission statement, printed on a plaque in the lobby, referenced the improvement of human health through scientific discovery.
What the plaque did not mention was that the Foundation controlled 77% of Novo Nordisk’s voting rights while holding only 28% of its shares. This structure – a legacy of Danish corporate tradition and the founder’s original intent – meant that the Foundation could appoint board members, approve strategy, and remove executives without the consent, or even the knowledge, of the investors who owned the other 72% of the company’s economic value.
Lars Rebien Sorensen understood this power better than anyone alive. He had been Novo Nordisk’s CEO for sixteen years before stepping down in 2017, presiding over the company’s transformation from a regional insulin manufacturer into a global diabetes powerhouse. Now, as Foundation chairman, he occupied the position that controlled the position that controlled the company. It was a Russian nesting doll of authority, and Sorensen sat at the center of it.
He was seventy years old and did not look it. His hair was silver but thick, his handshake firm, his recall of financial details almost unsettling. He attended every quarterly earnings call, read every analyst report, and maintained a network of contacts across the industry that would have been the envy of any sitting CEO. Retirement, in the conventional sense, had never occurred to him. He had simply traded one throne for the one behind it.
By mid-2024, Sorensen was worried.
Not about the stock price – that was still rising, still generating the dividends that funded the Foundation’s charitable work. He was worried about what the stock price was hiding. He had seen the CagriSema interim data before the analysts had, and what he saw troubled him. The efficacy numbers were good, but not good enough – not enough to create clear daylight between Novo’s next drug and Lilly’s current one. The safety profile had wrinkles that would require careful navigation with regulators. And the manufacturing timeline assumed everything would go right, which, in Sorensen’s experience, nothing ever did.
He placed a call to Helge Lund, the company’s board chairman, on a Tuesday afternoon in July.
“Helge, do you have a moment?”
Helge Lund was a particular type of Scandinavian executive – reserved, competent, allergic to drama. He had run Statoil, chaired BG Group during its acquisition by Shell, and now oversaw Novo Nordisk’s board with the same methodical calm he brought to everything. He was not a man who panicked. He was also not a man who ignored a phone call from Lars Rebien Sorensen.
“Lars.” His voice was neutral, which was how it always sounded. “What’s on your mind?”
“I want to talk about Lars.” Both men understood immediately which Lars was meant. “I want to talk about whether he’s ready for what’s coming.”
Lund paused. In the silence, the shape of the conversation became clear.
“You’re asking whether I think the CEO can handle a competitive war with Eli Lilly.”
“I’m asking whether we can afford to find out.”
This was how power worked at Novo Nordisk. Not through formal resolutions or public confrontations, but through conversations between two men – one who controlled the votes, one who chaired the board – conducted in the understated register of Danish corporate culture, where the most consequential statements were always the quietest.
Lund did not commit to anything in that first call. He said he would think about it. He said the board’s performance evaluation of Jorgensen was not due until autumn. He said it would be unwise to act on incomplete information.
Sorensen thanked him, hung up, and made a note in the leather-bound journal he kept on his desk. The note read: H.L. – not ready yet. Will be by December.
The CagriSema data arrived in December 2024, and it confirmed Sorensen’s fears.
The drug worked. It caused weight loss. It lowered blood sugar. But the headline number – the one that mattered to the market, the one that would determine whether Novo Nordisk could maintain its position – fell short of Zepbound. Not by much. A few percentage points of body weight reduction. In absolute terms, the difference was clinically modest. In market terms, it was catastrophic.
Novo Nordisk’s stock dropped eight percent on the day the data was released. Analysts who had written glowing reports six months earlier now published notes with titles like “Pipeline Questions Mount” and “Is the Semaglutide Story Over?” A Goldman Sachs analyst, in a client call that leaked within hours, said the phrase that would haunt the company for months: “Novo Nordisk is a one-molecule story, and they just told us the sequel isn’t as good as the original.”
In Bagsvaerd, Jorgensen convened an emergency strategy session. The mood in the room was grim but not desperate. CagriSema could still be optimized. The regulatory pathway was still viable. And the installed base of Ozempic and Wegovy patients represented an enormous commercial moat – switching drugs was not like switching laundry detergent.
“We have time,” Jorgensen told his team. “The market overreacted. We’ll show them.”
But in Copenhagen, at the Foundation’s offices, Sorensen was reading the same data and reaching a different conclusion. The market had not overreacted. The market had understood, faster than Jorgensen, that the rules of the GLP-1 war had changed. Novo Nordisk was no longer the unchallenged inventor surfing a wave of its own creation. It was an incumbent defending territory against a competitor with a better product and deeper pockets.
Sorensen opened his journal and wrote a single line: The time for patience has passed.
Through January and February of 2025, Sorensen made his calls. Not many – perhaps eight in total – but each one to a person who mattered. A Foundation trustee in Aarhus. A former colleague at the European Medicines Agency. Two board members he had known for decades. The conversations followed a pattern: a general discussion about Novo Nordisk’s competitive position, a careful expression of concern about strategic direction, and then – never explicit, always implied – a question about whether the current CEO was the right leader for the next phase.
He was not building a coalition. Not exactly. He was testing whether a coalition was possible.
It was.
The independent directors were nervous. They had watched the stock price stabilize after the initial CagriSema shock, but they had also watched Eli Lilly announce a $3 billion expansion of its manufacturing capacity, a deal to acquire the obesity biotech startup Metsera, and a marketing blitz for Zepbound that made Novo Nordisk’s efforts look timid by comparison. Lilly was not just competing; Lilly was trying to win so decisively that the war would be over before Novo could mount a response.
“Lars is a good manager,” one board member told Sorensen over dinner at Noma, the kind of restaurant where Copenhagen’s power class went to have conversations they did not want overheard. “But this isn’t a management problem anymore. This is a survival problem.”
“I agree,” Sorensen said. He took a sip of his wine and set the glass down carefully. “And I think we need to discuss what survival looks like.”
On a cold morning in March 2025, Jorgensen presented his five-year strategic plan to the full board. He had spent weeks preparing it. The slides were dense with data – market projections, pipeline timelines, manufacturing investments, geographic expansion targets. He walked through each section with the measured confidence of a man who had been running the company for eight years and believed he had earned the right to run it for eight more.
The plan was competent. It was thorough. It addressed the competitive threat from Eli Lilly, the pricing pressure from governments, and the manufacturing bottlenecks that had constrained supply. It proposed investments in oral formulations, next-generation molecules, and digital health platforms. It was, by any reasonable standard, a serious piece of strategic work.
It was also, Sorensen thought as he listened from his seat at the far end of the table, exactly the kind of plan you would expect from a man who did not understand that the ground had shifted beneath him.
Jorgensen’s plan assumed the future would be an evolution of the present – faster, bigger, more efficient, but fundamentally recognizable. It assumed Novo Nordisk could compete with Eli Lilly by doing more of what it had always done: better science, broader access, deeper patient relationships. It did not account for the possibility that the competitive war might require a fundamentally different kind of leader – someone willing to slash costs, take risks, and move with a speed that Jorgensen’s temperament and track record suggested he could not sustain.
As Jorgensen reached his concluding slide – a five-year revenue projection that showed steady growth returning by 2027 – he looked up from his notes and scanned the room for the reactions he expected: engaged nods, sharpened questions, the polite intensity of a board doing its job.
Instead, he saw something he had never seen before.
Helge Lund would not meet his eyes. The board chairman was staring at the table, his pen motionless, his expression carefully arranged into something that was not quite agreement and not quite anything else. It was the face of a man who had already made a decision and was simply enduring the formality of the presentation that preceded it.
Across the table, Lars Rebien Sorensen was writing. Not taking notes on the presentation – Jorgensen could tell the difference after years of reading rooms. Sorensen was writing something else entirely, his pen moving in the quick, purposeful strokes of a man composing a plan of his own.
Jorgensen felt the air leave the room, though no window had opened. He looked back down at his slides. He finished his presentation. He asked for questions.
The silence lasted four seconds. It was the longest four seconds of his career.
This is a work of fiction. While inspired by real events and public information, all characters, dialogue, and internal deliberations are entirely imagined. Any resemblance to actual private conversations or decisions is coincidental.
